Oncology medicines
WE AIM TO BUILD ON OUR POSITION AS A WORLD LEADER IN CANCER TREATMENT THROUGH CONTINUED GROWTH OF ARIMIDEX, FURTHER LAUNCHES AND LINE EXTENSIONS OF NEWER PRODUCTS SUCH AS FASLODEX, AND THE SUCCESSFUL INTRODUCTION OF NOVEL THERAPEUTIC APPROACHES CURRENTLY IN DEVELOPMENT, INCLUDING BOTH SMALL MOLECULE AND BIOLOGICAL DRUGS.
2007 IN BRIEF
- Arimidex sales up 10% to $1.7 billion. It remains the leading hormonal breast cancer therapy in the US, Japan and France.
- Casodex sales growth continued with total sales of over $1 billion, up 6%.
- Zoladex sales of over $1 billion, up 4%.
- ZD4054 progressed into phase III development for hormone-resistant prostate cancer.
- Phase III trials of Zactima in non-small cell lung cancer (NSCLC) and in medullary thyroid cancer continued.
- Pivotal trials of Recentin in colorectal cancer (CLC) and NSCLC continued to recruit patients.
MARKETED PRODUCTS
Arimidex (anastrozole) is the world’s leading aromatase inhibitor for the treatment of breast cancer.
Casodex (bicalutamide) is the world’s leading anti-androgen therapy for the treatment of prostate cancer.
Zoladex (goserelin acetate implant), in one- and three-month depots, is the world’s second largest LHRH agonist for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders.
Iressa (gefitinib) is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that acts to block signals for cancer cell growth and survival in non-small cell lung cancer.
Faslodex (fulvestrant) is an injectable oestrogen receptor antagonist for the treatment of breast cancer, with no known agonist effects, that down-regulates the oestrogen receptor.
Nolvadex (tamoxifen citrate) remains a widely prescribed breast cancer treatment outside the US.
Ethyol (amifostine) is used to help prevent certain side effects of specific types of chemotherapy and radiotherapy that are used to treat cancer.
Abraxane®(paclitaxel protein-bound particles for injectable suspension) (albumin-bound), discovered, developed and owned by Abraxis BioScience, Inc., uses a novel technology to deliver paclitaxel for the treatment of breast cancer. We co-promote Abraxane®in the US under an agreement with Abraxis.
